Results 141 to 150 of about 4,014 (178)
Some of the next articles are maybe not open access.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [PDF]
New England Journal of Medicine, 2015 BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
Brian Conway +2 more
exaly +2 more sources
Clinical Pharmacokinetics, 2018
The pharmacokinetics and safety of velpatasvir, a potent pangenotypic hepatitis C virus NS5A inhibitor, were evaluated in two hepatic impairment studies: a phase I study in hepatitis C virus-uninfected subjects and a phase III study (ASTRAL-4) in hepatitis C virus-infected patients.In the phase I study, subjects with moderate or severe hepatic ...
Erik Mogalian +11 more
openaire +2 more sources
The pharmacokinetics and safety of velpatasvir, a potent pangenotypic hepatitis C virus NS5A inhibitor, were evaluated in two hepatic impairment studies: a phase I study in hepatitis C virus-uninfected subjects and a phase III study (ASTRAL-4) in hepatitis C virus-infected patients.In the phase I study, subjects with moderate or severe hepatic ...
Erik Mogalian +11 more
openaire +2 more sources
Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1–4 HCV-Infected Liver Transplant Recipients [PDF]
Journal of Hepatology, 2018 BACKGROUND & AIMS Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after treatment (SVR12) in patients with genotype 1-6 HCV infection, and has no ...
Zoe Mariño +2 more
exaly +2 more sources
Sofosbuvir/velpatasvir/Sofosbuvir/velpatasvir/voxilaprevir
Reactions Weekly, 2023openaire +1 more source